Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clarity PharmaceuticalsASX:CU6 +9.40%33 EV-to-EBITDA is -6.08 as of Jul. 23, 2026. GuruFocus rates ASX:CU6 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clarity Pharmaceuticals's enterprise value is A$646.76 Mil.
Clarity Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-106.29 Mil. Therefore, Clarity Pharmaceuticals's EV-to-EBITDA for today is -6.08.
The historical rank and industry rank for Clarity Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ASX:CU6'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.08 Med: 0 Max: 0
Current: -6.08
ASX:CU6's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 12.15
vs ASX:CU6: -6.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clarity Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Clarity Pharmaceuticals's share price for today is A$2.56.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clarity Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CU6 vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Clarity Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarity Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clarity Pharmaceuticals's EV-to-EBITDA falls into.
Clarity Pharmaceuticals's current Enterprise Value is A$646.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clarity Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-106.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarity Pharmaceuticals (ASX:CU6) has a EV-to-EBITDA of -6.08 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clarity Pharmaceuticals. According to the industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 400 companies in the Biotechnology industry.
Is Clarity Pharmaceuticals' EV-to-EBITDA too high?
Clarity Pharmaceuticals' current EV-to-EBITDA is -6.08. Based on the distribution chart, Clarity Pharmaceuticals ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 400 companies for EV-to-EBITDA. This places Clarity Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.15, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clarity Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current EV-to-EBITDA is -6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current EV-to-EBITDA of -6.08. The current EV-to-EBITDA is -6.08. Clarity Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current EV-to-EBITDA is -6.08 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
33GF Score
Get the complete analysis for ASX:CU6
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CU6 has been successfully added to your 
